Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lisata Therapeutics Inc LSTA

Healthcare Biotechnology
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to... see more

Recent & Breaking News (NDAQ:LSTA)

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

GlobeNewswire September 12, 2023

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire September 6, 2023

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

GlobeNewswire September 5, 2023

Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers

PR Newswire August 15, 2023

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 14, 2023

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

GlobeNewswire August 8, 2023

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

GlobeNewswire August 7, 2023

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

GlobeNewswire July 11, 2023

Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference

GlobeNewswire June 12, 2023

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

GlobeNewswire May 24, 2023

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 9, 2023

Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time

GlobeNewswire May 2, 2023

Lisata Therapeutics Announces Participation in Upcoming Conferences in May

GlobeNewswire April 27, 2023

Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

GlobeNewswire April 20, 2023

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

GlobeNewswire April 19, 2023

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

GlobeNewswire April 18, 2023

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 30, 2023

Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

GlobeNewswire March 23, 2023

Lisata Therapeutics Announces Participation in Upcoming Conferences in February

GlobeNewswire February 1, 2023

Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 10, 2022